But in an increasingly competitive market for weight loss drugs, these are not the only options for people looking to lose ...

Eli Lilly’s LLY popular obesity drug, Zepbound showed better weight loss than Novo Nordisk’s Wegovy in a head-to-head study.

The following drugs are alternatives to Zepbound: Nurse practitioner Tim Nicaise tried everything to lose weight without success. Then his doctor prescribed the drug Contrave and his life changed.

Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...

Eli Lilly's key products, Mounjaro and Zepbound, dominate the U.S. weight loss market. Read more to see why I rate LLY stock ...

It didn’t take long for the shine to come off one of biotech’s recent IPO success stories, with BioAge Labs scrapping a phase ...

The stupendous success of Mounjaro and Zepbound has made Lilly the largest drugmaker with a market cap of more than $780 billion. Lilly’s stock has gone up by 590% in the past five years ...

Lilly’s obesity drug, Zepbound, showed an average weight loss of 20.2%, which was superior to 13.7% for Novo Nordisk’s Wegovy (semaglutide) in a first-ever head-to-head obesity study ...

Lilly’s obesity drug, Zepbound, showed an average weight loss of 20.2%, which was superior to 13.7% for Novo Nordisk’s Wegovy (semaglutide) in a first-ever head-to-head obesity study, SURMOUNT-5. This ...